心脏代谢并发症负担与心力衰竭结果之间的关联
Carine E Hamo1, Xiyue Li2, Chiadi E Ndumele3
1Leon H. Charney Division of Cardiology, Department of Medicine New York University School of Medicine New York NY.
Journal of the American Heart Association
|January 23, 2025
概括
患有心力衰竭 (HF) 和更严重的心脏代谢疾病 (如失控的糖尿病和高血压) 的患者面临住院住院的风险更高. 管理这些并发症是减少HF发病率的关键.
科学领域:
- 心脏病学 心脏病学
- 代谢医学是一种代谢医学.
- 公共卫生 公共卫生
背景情况:
- 心力衰竭 (HF) 经常与诸如肥胖,糖尿病和高血压等心脏代谢疾病同时发生.
- 这些并发症的患病率在管理HF患者中构成了重大挑战.
研究的目的:
- 调查心脏代谢性并发症的严重程度与被诊断为心力衰竭的患者住院率之间的关联.
- 为了确定非控制的心脏代谢条件的较高负担是否与心力衰竭的入院增加相关.
主要方法:
- 对HF成年患者 (≥18岁) 电子健康记录的回顾性分析.
- 患者根据严重并发症的数量进行分层:高血压,糖尿病和肥胖症,以特定的临床值来定义 (SBP ≥160 mmHg,HbA1c ≥8%,BMI ≥35 kg/m2).
- 考克斯回归模型被用来评估一年内全因和特定于HF的住院住院的风险,并根据各种人口和临床因素进行调整. 分析按HF类型分层 (保留与减少的喷射分数).
主要成果:
- 该研究包括26,800名高风患者,其中16%的人在一年内住院治疗.
- 与没有并发症的人相比,患有1个或2到3种严重不受控制的心脏代谢并发症的个体显著增加了全因住院的风险 (HR分别为1.23和1.57).
- 对心力衰竭住院患者也观察到类似的关联,这些发现在整个心力衰竭中与保留和减少喷射分数子组一致.
结论:
- 严重的心脏代谢并发症的增加负担与心力衰竭患者全因住院的风险更高显著相关.
- 这些发现强调了积极管理和准不受控制的心脏代谢疾病的重要性,以减轻HF患者的发病率和减少住院治疗.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.4K
04:20Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
5.7K
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:29Pathophysiology of Cardiac Performance
520
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
520
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
376
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K